Mallery I. Breban
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mallery I. Breban has a total of 306 co-authors. Here are the top co-authors by number of shared publications:
- Nathan D. Grubaugh
Yale School of Public Health 4 Department of Epidemiology of Microbial Diseases New Haven, CT
13 shared publications - Chantal B. F. Vogels
Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
10 shared publications - Carolina Lucas
Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA
7 shared publications Chrispin Chaguza
Department of Epidemiology of Microbial Diseases Department of Epidemiology of Microbial Diseases Yale School of Public Health Yale Schoo
7 shared publicationsDaniel J. Park
5 shared publicationsErika Buzby
5 shared publications
Latest Publications
- 2 September 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (10)
Serotype skewing and immune imprinting shape response to the tetravalent dengue virus Qdenga vaccine
Dengue causes over 390 million annual infections globally. Qdenga (TAK-003), the only widely available dengue vaccine, has an incompletely defined immunological profile. We performed longitudinal immunological profiling of 110 adults from a dengue-endemic region, including older adults (≥65 years), to assess the effects of immune imprinting and vaccine design on humoral and cellular immunity. Qdenga elicited B and T cell activation across groups but generated serostatus-dependent, serotype-skewed antibody responses. Only 8% of DENV-naïve individuals developed tetravalent neutralizing responses, whereas one-third responded to a single serotype, predominantly DENV-2, the vaccine backbone. DENV-exposed individuals mounted broader responses shaped by preexisting immunity, yet DENV-4 neutralization remained consistently poor. Neutralizing antibody titers plateaued after the first dose, with no increase following the second. These findings clarify why balanced tetravalent immunity is rarely achieved with Qdenga and demonstrate that both immune imprinting and vaccine backbone limit the breadth and magnitude of the responses. This has important implications for deployment, long-term protection in naive populations, and DENV-4–targeted boosters.
- 2 September 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (10)
Serotype skewing and immune imprinting shape response to the tetravalent dengue virus Qdenga vaccine
Dengue causes over 390 million annual infections globally. Qdenga (TAK-003), the only widely available dengue vaccine, has an incompletely defined immunological profile. We performed longitudinal immunological profiling of 110 adults from a dengue-endemic region, including older adults (≥65 years), to assess the effects of immune imprinting and vaccine design on humoral and cellular immunity. Qdenga elicited B and T cell activation across groups but generated serostatus-dependent, serotype-skewed antibody responses. Only 8% of DENV-naïve individuals developed tetravalent neutralizing responses, whereas one-third responded to a single serotype, predominantly DENV-2, the vaccine backbone. DENV-exposed individuals mounted broader responses shaped by preexisting immunity, yet DENV-4 neutralization remained consistently poor. Neutralizing antibody titers plateaued after the first dose, with no increase following the second. These findings clarify why balanced tetravalent immunity is rarely achieved with Qdenga and demonstrate that both immune imprinting and vaccine backbone limit the breadth and magnitude of the responses. This has important implications for deployment, long-term protection in naive populations, and DENV-4–targeted boosters.
- Open Access
- 16 January 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (1) , 116844
Genomic epidemiology of dengue virus 2 and 3 reveals repeated introductions and exportations of several lineages in Colombia
- 16 January 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (1) , 116844
Open AccessGenomic epidemiology of dengue virus 2 and 3 reveals repeated introductions and exportations of several lineages in Colombia
- Open Access
Genomic epidemiology of dengue virus 2 and 3 reveals repeated introductions and exportations of several lineages in Colombia
SUMMARY: Dengue fever, a major mosquito-borne viral disease, is transmitted by Aedes mosquitoes and poses a significant global health burden. Despite extensive research, the spatiotemporal dynamics of dengue virus (DENV) lineages in Colombia remain understudied. Here we analyze 11,443 complete genome sequences from Colombia and the Americas to map the genomic epidemiology of DENV-2 and DENV-3. Phylogeographic reconstruction revealed multiple independent introductions and exportations of the DENV-2 II and III lineages, as well as the DENV-3 lineage III C.2, underscoring Colombia’s critical role both as a source and a sink of viral traffic within the Americas. Antigenic profiling demonstrated distinct clustering of emergent lineages in antigenic space, consistent with immune-escape–driven turnover. These results highlight the necessity of sustained, high-resolution genomic surveillance to guide targeted public-health interventions and mitigate dengue transmission across the region.
Open AccessGenomic epidemiology of dengue virus 2 and 3 reveals repeated introductions and exportations of several lineages in Colombia
SUMMARY: Dengue fever, a major mosquito-borne viral disease, is transmitted by Aedes mosquitoes and poses a significant global health burden. Despite extensive research, the spatiotemporal dynamics of dengue virus (DENV) lineages in Colombia remain understudied. Here we analyze 11,443 complete genome sequences from Colombia and the Americas to map the genomic epidemiology of DENV-2 and DENV-3. Phylogeographic reconstruction revealed multiple independent introductions and exportations of the DENV-2 II and III lineages, as well as the DENV-3 lineage III C.2, underscoring Colombia’s critical role both as a source and a sink of viral traffic within the Americas. Antigenic profiling demonstrated distinct clustering of emergent lineages in antigenic space, consistent with immune-escape–driven turnover. These results highlight the necessity of sustained, high-resolution genomic surveillance to guide targeted public-health interventions and mitigate dengue transmission across the region.
- Open Access
- 29 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-12
Implications of successive blood feeding on Wolbachia-mediated dengue virus inhibition in Aedes aegypti mosquitoes
Wolbachia is a promising strategy to inhibit dengue virus (DENV) transmission by Ae. aegypti mosquitoes. Laboratory studies assessing DENV inhibition by Wolbachia typically have not considered natural frequent mosquito blood feeding behavior. Here, we determine the impact of successive feeding on DENV-2 transmission by Ae. aegypti in the presence or absence of Wolbachia (wAlbB and wMelM strains). We show that successive feeding shortens the extrinsic incubation period (EIP) in wildtype (WT; without Wolbachia) and wAlbB mosquitoes through enhanced dissemination. Feeding empirical data into models showed that successive feeding increases the probability of WT and wAlbB mosquitoes surviving beyond the EIP. Importantly, the more epidemiologically relevant comparison of the odds of wAlbB mosquitoes surviving beyond the EIP relative to WT, reveals a larger impact of successive feeding on WT than wAlbB. This indicates a strong inhibitory effect of Wolbachia even in the context of natural frequent mosquito blood feeding behavior.
- 29 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-12
Open AccessImplications of successive blood feeding on Wolbachia-mediated dengue virus inhibition in Aedes aegypti mosquitoes
Wolbachia is a promising strategy to inhibit dengue virus (DENV) transmission by Ae. aegypti mosquitoes. Laboratory studies assessing DENV inhibition by Wolbachia typically have not considered natural frequent mosquito blood feeding behavior. Here, we determine the impact of successive feeding on DENV-2 transmission by Ae. aegypti in the presence or absence of Wolbachia (wAlbB and wMelM strains). We show that successive feeding shortens the extrinsic incubation period (EIP) in wildtype (WT; without Wolbachia) and wAlbB mosquitoes through enhanced dissemination. Feeding empirical data into models showed that successive feeding increases the probability of WT and wAlbB mosquitoes surviving beyond the EIP. Importantly, the more epidemiologically relevant comparison of the odds of wAlbB mosquitoes surviving beyond the EIP relative to WT, reveals a larger impact of successive feeding on WT than wAlbB. This indicates a strong inhibitory effect of Wolbachia even in the context of natural frequent mosquito blood feeding behavior.
- Open Access
- 5 March 2024
- Published by Springer Nature in Research Square
The impact of antigenic distance on Orthopoxvirus Vaccination and Mpox Infection for cross-protective immunity
Immunological memory mediates rapid protection following infection or vaccination including heterologous exposure. However, cross-reactive memory responses in humans remain poorly characterized. We explored the longevity and specificity of cross-protective responses to orthopoxviruses through smallpox vaccination and Mpox virus (MPXV) infection. Smallpox vaccination using Vaccinia virus (VACV)-based vaccines provides a unique opportunity to study long-term cross-protective immunity without antigen re-exposure. We assessed systemic and mucosal responses in four human cohorts, including first-(Dryvax) and/or third-generation (JYNNEOS) smallpox vaccine recipients (vaccinated 1 week-80 years ago), along with Mpox-infected individuals. First-and third-generation smallpox vaccines elicited strong VACV- and MPXV-specific antibodies. VACV-neutralizing antibodies persisted for decades in first-generation vaccine recipients and were further enhanced after JYNNEOS vaccination. However, despite the high levels of anti-MPXV-specific antibodies in the plasma, cross-neutralization activity was directly correlated with the antigenic distance. Higher neutralization was observed for the cowpox virus (CWPXV) than for MPXV, which showed lower antigenic conservation with VACV. Similarly, Mpox-infected patients had lower neutralization titers for VACV than for CWPXV. Individuals who received vaccination boosters showed more robust, diverse, and prolonged cross-neutralizing responses. Long-term memory analysis revealed an increase in neutralization capacity for VACV over decades, with 80-years-old displaying the most robust humoral response, although this trend was not observed for cross-reactive antigens. Finally, T-cell reactivity to VACV and MPXV epitopes was detected decades post-vaccination, suggesting a role of long-lasting cross-reactive T-cell memory responses in vaccine efficacy. Our findings underscore the pivotal influence of antigenic distance on vaccine effectiveness with implications for cross-protective vaccine design.
- 5 March 2024
- Published by Springer Nature in Research Square
Open AccessThe impact of antigenic distance on Orthopoxvirus Vaccination and Mpox Infection for cross-protective immunity
Immunological memory mediates rapid protection following infection or vaccination including heterologous exposure. However, cross-reactive memory responses in humans remain poorly characterized. We explored the longevity and specificity of cross-protective responses to orthopoxviruses through smallpox vaccination and Mpox virus (MPXV) infection. Smallpox vaccination using Vaccinia virus (VACV)-based vaccines provides a unique opportunity to study long-term cross-protective immunity without antigen re-exposure. We assessed systemic and mucosal responses in four human cohorts, including first-(Dryvax) and/or third-generation (JYNNEOS) smallpox vaccine recipients (vaccinated 1 week-80 years ago), along with Mpox-infected individuals. First-and third-generation smallpox vaccines elicited strong VACV- and MPXV-specific antibodies. VACV-neutralizing antibodies persisted for decades in first-generation vaccine recipients and were further enhanced after JYNNEOS vaccination. However, despite the high levels of anti-MPXV-specific antibodies in the plasma, cross-neutralization activity was directly correlated with the antigenic distance. Higher neutralization was observed for the cowpox virus (CWPXV) than for MPXV, which showed lower antigenic conservation with VACV. Similarly, Mpox-infected patients had lower neutralization titers for VACV than for CWPXV. Individuals who received vaccination boosters showed more robust, diverse, and prolonged cross-neutralizing responses. Long-term memory analysis revealed an increase in neutralization capacity for VACV over decades, with 80-years-old displaying the most robust humoral response, although this trend was not observed for cross-reactive antigens. Finally, T-cell reactivity to VACV and MPXV epitopes was detected decades post-vaccination, suggesting a role of long-lasting cross-reactive T-cell memory responses in vaccine efficacy. Our findings underscore the pivotal influence of antigenic distance on vaccine effectiveness with implications for cross-protective vaccine design.
- Open Access
The impact of antigenic distance on Orthopoxvirus Vaccination and Mpox Infection for cross-protective immunity
Immunological memory mediates rapid protection following infection or vaccination including heterologous exposure. However, cross-reactive memory responses in humans remain poorly characterized. We explored the longevity and specificity of cross-protective responses to orthopoxviruses through smallpox vaccination and Mpox virus (MPXV) infection. Smallpox vaccination using Vaccinia virus (VACV)-based vaccines provides a unique opportunity to study long-term cross-protective immunity without antigen re-exposure. We assessed systemic and mucosal responses in four human cohorts, including first-(Dryvax) and/or third-generation (JYNNEOS) smallpox vaccine recipients (vaccinated 1 week-80 years ago), along with Mpox-infected individuals. First-and third-generation smallpox vaccines elicited strong VACV- and MPXV-specific antibodies. VACV-neutralizing antibodies persisted for decades in first-generation vaccine recipients and were further enhanced after JYNNEOS vaccination. However, despite the high levels of anti-MPXV-specific antibodies in the plasma, cross-neutralization activity was directly correlated with the antigenic distance. Higher neutralization was observed for the cowpox virus (CWPXV) than for MPXV, which showed lower antigenic conservation with VACV. Similarly, Mpox-infected patients had lower neutralization titers for VACV than for CWPXV. Individuals who received vaccination boosters showed more robust, diverse, and prolonged cross-neutralizing responses. Long-term memory analysis revealed an increase in neutralization capacity for VACV over decades, with 80-years-old displaying the most robust humoral response, although this trend was not observed for cross-reactive antigens. Finally, T-cell reactivity to VACV and MPXV epitopes was detected decades post-vaccination, suggesting a role of long-lasting cross-reactive T-cell memory responses in vaccine efficacy. Our findings underscore the pivotal influence of antigenic distance on vaccine effectiveness with implications for cross-protective vaccine design.
Open AccessThe impact of antigenic distance on Orthopoxvirus Vaccination and Mpox Infection for cross-protective immunity
Immunological memory mediates rapid protection following infection or vaccination including heterologous exposure. However, cross-reactive memory responses in humans remain poorly characterized. We explored the longevity and specificity of cross-protective responses to orthopoxviruses through smallpox vaccination and Mpox virus (MPXV) infection. Smallpox vaccination using Vaccinia virus (VACV)-based vaccines provides a unique opportunity to study long-term cross-protective immunity without antigen re-exposure. We assessed systemic and mucosal responses in four human cohorts, including first-(Dryvax) and/or third-generation (JYNNEOS) smallpox vaccine recipients (vaccinated 1 week-80 years ago), along with Mpox-infected individuals. First-and third-generation smallpox vaccines elicited strong VACV- and MPXV-specific antibodies. VACV-neutralizing antibodies persisted for decades in first-generation vaccine recipients and were further enhanced after JYNNEOS vaccination. However, despite the high levels of anti-MPXV-specific antibodies in the plasma, cross-neutralization activity was directly correlated with the antigenic distance. Higher neutralization was observed for the cowpox virus (CWPXV) than for MPXV, which showed lower antigenic conservation with VACV. Similarly, Mpox-infected patients had lower neutralization titers for VACV than for CWPXV. Individuals who received vaccination boosters showed more robust, diverse, and prolonged cross-neutralizing responses. Long-term memory analysis revealed an increase in neutralization capacity for VACV over decades, with 80-years-old displaying the most robust humoral response, although this trend was not observed for cross-reactive antigens. Finally, T-cell reactivity to VACV and MPXV epitopes was detected decades post-vaccination, suggesting a role of long-lasting cross-reactive T-cell memory responses in vaccine efficacy. Our findings underscore the pivotal influence of antigenic distance on vaccine effectiveness with implications for cross-protective vaccine design.
- Open Access
Survey of white-footed mice in Connecticut, USA reveals low SARS-CoV-2 seroprevalence and infection with divergent betacoronaviruses
Diverse mammalian species display susceptibility to and infection with SARS-CoV-2. Potential SARS-CoV-2 spillback into rodents is understudied despite their host role for numerous zoonoses and human proximity. We assessed exposure and infection among white-footed mice ( Peromyscus leucopus ) in Connecticut, USA. We observed 1% (6/540) wild-type neutralizing antibody seroprevalence among 2020-2022 residential mice with no cross-neutralization of variants. We detected no SARS-CoV-2 infections via RT-qPCR, but identified non-SARS-CoV-2 betacoronavirus infections via pan-coronavirus PCR among 1% (5/468) of residential mice. Sequencing revealed two divergent betacoronaviruses, preliminarily named Peromyscus coronavirus-1 and -2 . Both belong to the Betacoronavirus 1 species and are ∼90% identical to the closest known relative, Porcine hemagglutinating encephalomyelitis virus . Low SARS-CoV-2 seroprevalence suggests white-footed mice may not be sufficiently susceptible or exposed to SARS-CoV-2 to present a long-term human health risk. However, the discovery of divergent, non-SARS-CoV-2 betacoronaviruses expands the diversity of known rodent coronaviruses and further investigation is required to understand their transmission extent.
Open AccessSurvey of white-footed mice in Connecticut, USA reveals low SARS-CoV-2 seroprevalence and infection with divergent betacoronaviruses
Diverse mammalian species display susceptibility to and infection with SARS-CoV-2. Potential SARS-CoV-2 spillback into rodents is understudied despite their host role for numerous zoonoses and human proximity. We assessed exposure and infection among white-footed mice ( Peromyscus leucopus ) in Connecticut, USA. We observed 1% (6/540) wild-type neutralizing antibody seroprevalence among 2020-2022 residential mice with no cross-neutralization of variants. We detected no SARS-CoV-2 infections via RT-qPCR, but identified non-SARS-CoV-2 betacoronavirus infections via pan-coronavirus PCR among 1% (5/468) of residential mice. Sequencing revealed two divergent betacoronaviruses, preliminarily named Peromyscus coronavirus-1 and -2 . Both belong to the Betacoronavirus 1 species and are ∼90% identical to the closest known relative, Porcine hemagglutinating encephalomyelitis virus . Low SARS-CoV-2 seroprevalence suggests white-footed mice may not be sufficiently susceptible or exposed to SARS-CoV-2 to present a long-term human health risk. However, the discovery of divergent, non-SARS-CoV-2 betacoronaviruses expands the diversity of known rodent coronaviruses and further investigation is required to understand their transmission extent.
- Open Access
- 2 August 2023
- Published by Springer Nature
DengueSeq: A pan-serotype whole genome amplicon sequencing protocol for dengue virus v3
Version 3 updates: Updated abstract Included link to preprint and bioinformatics pipeline Added links to additional library prep kits Included DENV2 and DENV4 sylvatic reference genomes and BED files Changed primer names in BED files DengueSeq preprint: https://www.medrxiv.org/content/10.1101/2023.10.13.23296997v1 Bioinformatics pipeline: https://github.com/grubaughlab/DENV_pipeline/tree/v1.0 Background The increasing burden of dengue virus on public health due to more explosive and frequent outbreaks highlights the need for improved surveillance and control. Genomic surveillance of dengue virus not only provides important insights into the emergence and spread of genetically diverse serotypes and genotypes, but it is also critical to monitor the effectiveness of newly implemented control strategies. Here, we present DengueSeq, an amplicon sequencing protocol, which enables whole-genome sequencing of all four dengue virus serotypes. Results We developed primer schemes for the four dengue virus serotypes, which can be combined into a pan-serotype approach. We validated both approaches using genetically diverse virus stocks and clinical specimens that contained a range of virus copies. High genome coverage (>95%) was achieved for all genotypes, except DENV2 (genotype VI) and DENV 4 (genotype IV) sylvatics, with similar performance of the serotype-specific and pan-serotype approaches. The limit of detection to reach 70% coverage was 10-100 RNA copies/μL for all four serotypes, which is similar to other commonly used primer schemes. DengueSeq facilitates the sequencing of samples without known serotypes, allows the detection of multiple serotypes in the same sample, and can be used with a variety of library prep kits and sequencing instruments. Conclusions DengueSeq was systematically evaluated with virus stocks and clinical specimens spanning the genetic diversity within each of the four dengue virus serotypes. The primer schemes can be plugged into existing amplicon sequencing workflows to facilitate the global need for expanded dengue virus genomic surveillance. Link to DengueSeq preprint.
- 2 August 2023
- Published by Springer Nature
Open AccessDengueSeq: A pan-serotype whole genome amplicon sequencing protocol for dengue virus v3
Version 3 updates: Updated abstract Included link to preprint and bioinformatics pipeline Added links to additional library prep kits Included DENV2 and DENV4 sylvatic reference genomes and BED files Changed primer names in BED files DengueSeq preprint: https://www.medrxiv.org/content/10.1101/2023.10.13.23296997v1 Bioinformatics pipeline: https://github.com/grubaughlab/DENV_pipeline/tree/v1.0 Background The increasing burden of dengue virus on public health due to more explosive and frequent outbreaks highlights the need for improved surveillance and control. Genomic surveillance of dengue virus not only provides important insights into the emergence and spread of genetically diverse serotypes and genotypes, but it is also critical to monitor the effectiveness of newly implemented control strategies. Here, we present DengueSeq, an amplicon sequencing protocol, which enables whole-genome sequencing of all four dengue virus serotypes. Results We developed primer schemes for the four dengue virus serotypes, which can be combined into a pan-serotype approach. We validated both approaches using genetically diverse virus stocks and clinical specimens that contained a range of virus copies. High genome coverage (>95%) was achieved for all genotypes, except DENV2 (genotype VI) and DENV 4 (genotype IV) sylvatics, with similar performance of the serotype-specific and pan-serotype approaches. The limit of detection to reach 70% coverage was 10-100 RNA copies/μL for all four serotypes, which is similar to other commonly used primer schemes. DengueSeq facilitates the sequencing of samples without known serotypes, allows the detection of multiple serotypes in the same sample, and can be used with a variety of library prep kits and sequencing instruments. Conclusions DengueSeq was systematically evaluated with virus stocks and clinical specimens spanning the genetic diversity within each of the four dengue virus serotypes. The primer schemes can be plugged into existing amplicon sequencing workflows to facilitate the global need for expanded dengue virus genomic surveillance. Link to DengueSeq preprint.
- Open Access
- 1 February 2023
- Published by Springer Nature
DengueSeq: A pan-serotype whole genome amplicon sequencing protocol for dengue virus v2
Version 2 updates: Updated the DENV3 primer file (DENV3_Primer-Scheme.xlsx) with correct version Background Amplicon-based sequencing (PrimalSeq) was developed in response to the Zika virus epidemic due to difficulties generating complete genomes using metagenomic approaches [1,2]. Later this approach was adapted as the primary sequencing method for SARS-CoV-2 (i.e. the “ARTIC” protocol) [3]. During the COVID-19 pandemic, investments in genomic infrastructure have resulted in a significant increase in sequencing capacity leading to a record number of over 14 million publicly available SARS-CoV-2 genomes. This expanded sequencing capacity can be utilized to improve genomic surveillance of other viruses, by swapping out components such as primer schemes. The COVID-19 pandemic further exemplifies how genomic surveillance can help to track the emergence and spread of variants, facilitate vaccine development, and inform diagnostics and therapeutics. Increased genomic surveillance of other viruses of public health concern, such as the mosquito-borne dengue virus, is needed to reduce the future burden of disease. Particularly, genomic surveillance can help to monitor the roll out of novel control strategies such as vaccines and release of mosquitoes carrying the virus-inhibiting Wolbachia bacteria. However, the majority of currently available sequences are partial, making them unsuitable to monitor and refine novel control tools. Here, we developed and validated primer schemes for all four dengue virus serotypes to improve whole-genome sequencing using an amplicon-based sequencing approach. The serotype-specific primers can be used individually or combined as a universal pan-serotype dengue virus amplicon-based sequencing approach. Overview of design We used PrimalScheme (https://primalscheme.com/) to generate four serotype-specific dengue virus primer schemes (serotypes 1-4). For each primer scheme, we selected 10 publicly available genomes that represent the genetic diversity within each serotype. As reference genomes, we used the four serotype-specific reference genomes available on GenBank (DENV1: NC_001477.1, DENV2: NC_001474.2, DENV3: NC_001475.2, DENV4: NC_002640.1). Each primer scheme consists of 35-37 primer pairs with an amplicon length of ~400 bp. Initial validation We validated the four primer schemes with dengue virus stocks that we obtained from the Yale Arbovirus Research Unit (YARU) and World Reference Center for Emerging Viruses and Arboviruses (WRCEVA, UTMB) collections. These virus stocks spanned the defined genotypes within each of the four serotypes. Serotypes were confirmed and PCR cycle threshold (Ct) values were determined with the CDC real-time RT-PCR assay [4]. We sequenced dengue viruses using the Illumina COVIDSeq test (RUO version) and generated consensus genomes at a depth of coverage of 20X using iVar (version 1.3.1). Initially, we sequenced undiluted virus stocks with the serotype-specific assay and found high coverage across all genotypes within each serotype, except for sylvatic dengue virus serotype 2 (genotype VI; Figure 1). Next, we selected 1-2 viruses for each genotype and diluted these viruses until no RNA was detected. By sequencing these diluted viruses we found that we were able to generate near-complete genomes for samples containing at least ~100 RNA copies per μL (PCR Ct value of approximately 30) for each serotype. Some selected viruses had mismatches with the real-time RT-PCR assay, resulting in reduced sensitivity of the assay. As a result, there may be varying levels of genome coverage for samples that were not detected by the real-time RT-PCR assay. To facilitate high-throughput sequencing, we developed a single pan-serotype dengue virus approach that can be used for all four serotypes. By mixing the four primer schemes and increasing the working concentration of the primers to 20 μM, we were able to achieve similar genome coverage as compared to the serotype-specific approach (Figure 2). This pan-serotype protocol for dengue virus is particularly useful when the serotype is unknown, when there are co-infections with multiple serotypes, or when multiple serotypes are included in a single sequencing run. Conclusion In this protocol we present the initial validation of a whole genome amplicon-based sequencing approach for all four dengue virus serotypes. We show that the four primer schemes can be used as serotype-specific or combined pan-serotype dengue virus whole genome sequencing protocol. The newly developed primer schemes can be used with currently established amplicon-based sequencing workflows, like COVIDseq, with minimal change to the protocol. Further testing involves sequencing of clinical samples. Our ultimate goal is to help increase capacity for whole genome dengue virus sequencing. Acknowledgements We would like to acknowledge Philip Armstrong, Doug Brackney, and team (Connecticut Agricultural Experiment Station) for generously providing dengue virus samples from the Yale Arbovirus Research Unit collection, Kenneth Plante and team (The University of Texas Medical Branch) for generously providing dengue virus samples from the World Reference Center for Emerging Viruses and Arboviruses collection, and Mary Petrone and Isabel Ott for preparation of virus stocks. References 1. Quick J, Grubaugh ND, Pullan ST, Claro IM, Smith AD, Gangavarapu K, et al. Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples. Nat Protoc. 2017;12: 1261–1276. 2. Grubaugh ND, Gangavarapu K, Quick J, Matteson NL, De Jesus JG, Main BJ, et al. An amplicon-based sequencing framework for accurately measuring intrahost virus diversity using PrimalSeq and iVar. Genome Biol. 2019;20: 8. 3. Artic Network. [cited 25 Jul 2022]. Available: https://artic.network/ncov-2019 4. Santiago GA, Vergne E, Quiles Y, Cosme J, Vazquez J, Medina JF, et al. Analytical and clinical...
- 1 February 2023
- Published by Springer Nature
Open AccessDengueSeq: A pan-serotype whole genome amplicon sequencing protocol for dengue virus v2
Version 2 updates: Updated the DENV3 primer file (DENV3_Primer-Scheme.xlsx) with correct version Background Amplicon-based sequencing (PrimalSeq) was developed in response to the Zika virus epidemic due to difficulties generating complete genomes using metagenomic approaches [1,2]. Later this approach was adapted as the primary sequencing method for SARS-CoV-2 (i.e. the “ARTIC” protocol) [3]. During the COVID-19 pandemic, investments in genomic infrastructure have resulted in a significant increase in sequencing capacity leading to a record number of over 14 million publicly available SARS-CoV-2 genomes. This expanded sequencing capacity can be utilized to improve genomic surveillance of other viruses, by swapping out components such as primer schemes. The COVID-19 pandemic further exemplifies how genomic surveillance can help to track the emergence and spread of variants, facilitate vaccine development, and inform diagnostics and therapeutics. Increased genomic surveillance of other viruses of public health concern, such as the mosquito-borne dengue virus, is needed to reduce the future burden of disease. Particularly, genomic surveillance can help to monitor the roll out of novel control strategies such as vaccines and release of mosquitoes carrying the virus-inhibiting Wolbachia bacteria. However, the majority of currently available sequences are partial, making them unsuitable to monitor and refine novel control tools. Here, we developed and validated primer schemes for all four dengue virus serotypes to improve whole-genome sequencing using an amplicon-based sequencing approach. The serotype-specific primers can be used individually or combined as a universal pan-serotype dengue virus amplicon-based sequencing approach. Overview of design We used PrimalScheme (https://primalscheme.com/) to generate four serotype-specific dengue virus primer schemes (serotypes 1-4). For each primer scheme, we selected 10 publicly available genomes that represent the genetic diversity within each serotype. As reference genomes, we used the four serotype-specific reference genomes available on GenBank (DENV1: NC_001477.1, DENV2: NC_001474.2, DENV3: NC_001475.2, DENV4: NC_002640.1). Each primer scheme consists of 35-37 primer pairs with an amplicon length of ~400 bp. Initial validation We validated the four primer schemes with dengue virus stocks that we obtained from the Yale Arbovirus Research Unit (YARU) and World Reference Center for Emerging Viruses and Arboviruses (WRCEVA, UTMB) collections. These virus stocks spanned the defined genotypes within each of the four serotypes. Serotypes were confirmed and PCR cycle threshold (Ct) values were determined with the CDC real-time RT-PCR assay [4]. We sequenced dengue viruses using the Illumina COVIDSeq test (RUO version) and generated consensus genomes at a depth of coverage of 20X using iVar (version 1.3.1). Initially, we sequenced undiluted virus stocks with the serotype-specific assay and found high coverage across all genotypes within each serotype, except for sylvatic dengue virus serotype 2 (genotype VI; Figure 1). Next, we selected 1-2 viruses for each genotype and diluted these viruses until no RNA was detected. By sequencing these diluted viruses we found that we were able to generate near-complete genomes for samples containing at least ~100 RNA copies per μL (PCR Ct value of approximately 30) for each serotype. Some selected viruses had mismatches with the real-time RT-PCR assay, resulting in reduced sensitivity of the assay. As a result, there may be varying levels of genome coverage for samples that were not detected by the real-time RT-PCR assay. To facilitate high-throughput sequencing, we developed a single pan-serotype dengue virus approach that can be used for all four serotypes. By mixing the four primer schemes and increasing the working concentration of the primers to 20 μM, we were able to achieve similar genome coverage as compared to the serotype-specific approach (Figure 2). This pan-serotype protocol for dengue virus is particularly useful when the serotype is unknown, when there are co-infections with multiple serotypes, or when multiple serotypes are included in a single sequencing run. Conclusion In this protocol we present the initial validation of a whole genome amplicon-based sequencing approach for all four dengue virus serotypes. We show that the four primer schemes can be used as serotype-specific or combined pan-serotype dengue virus whole genome sequencing protocol. The newly developed primer schemes can be used with currently established amplicon-based sequencing workflows, like COVIDseq, with minimal change to the protocol. Further testing involves sequencing of clinical samples. Our ultimate goal is to help increase capacity for whole genome dengue virus sequencing. Acknowledgements We would like to acknowledge Philip Armstrong, Doug Brackney, and team (Connecticut Agricultural Experiment Station) for generously providing dengue virus samples from the Yale Arbovirus Research Unit collection, Kenneth Plante and team (The University of Texas Medical Branch) for generously providing dengue virus samples from the World Reference Center for Emerging Viruses and Arboviruses collection, and Mary Petrone and Isabel Ott for preparation of virus stocks. References 1. Quick J, Grubaugh ND, Pullan ST, Claro IM, Smith AD, Gangavarapu K, et al. Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples. Nat Protoc. 2017;12: 1261–1276. 2. Grubaugh ND, Gangavarapu K, Quick J, Matteson NL, De Jesus JG, Main BJ, et al. An amplicon-based sequencing framework for accurately measuring intrahost virus diversity using PrimalSeq and iVar. Genome Biol. 2019;20: 8. 3. Artic Network. [cited 25 Jul 2022]. Available: https://artic.network/ncov-2019 4. Santiago GA, Vergne E, Quiles Y, Cosme J, Vazquez J, Medina JF, et al. Analytical and clinical...
- Open Access
- 12 December 2022
- Published by Springer Nature
Monkeypox virus multiplexed PCR amplicon sequencing (PrimalSeq) v2
Version 5 Updates: Release of updated primer scheme (v1.1) that includes 11 additional primers to be spiked into the original primer scheme to improve coverage when sequencing clade I viruses. See materials tab for primer information and step 8 for new clade I reference and BED files. Complete validation study: https://doi.org/10.1101/2022.10.14.22280783 Background: The current global outbreak of human Monkeypox virus (hMPXV) concurrent with an ongoing SARS-CoV-2 pandemic has further highlighted the need for genomic surveillance and pathogen whole genome sequencing. While metagenomic and hybrid capture sequencing approaches were used to sequence many of the early mpox cases, the viability of these methods is dependent on samples with high viral DNA concentrations. Given the atypical clinical presentation of cases associated with the current outbreak and uncertainty regarding viral load across both the course of infection and anatomical body sites, there is a strong need for a more sensitive and broadly applicable sequencing approach. Amplicon-based sequencing (PrimalSeq) was initially developed for sequencing of Zika virus, and later adapted as the main sequencing approach for SARS-CoV-2. Here, we used PrimalScheme to design a primer scheme for hMPXV and we validated it with widely used SARS-CoV-2 sequencing protocols. Based on initial validation, our approach shows notably higher depth and breadth of coverage across the genome, particularly with higher PCR cycle threshold (Ct) samples, as compared to metagenomic sequencing. While further testing is needed, the early success of this approach has significant implications for sequencing efforts of the current hMPXV outbreak and serves as a proof of concept of amplicon-based sequencing for use with other large-genome DNA viruses and potentially bacterial genomes. Overview of Design: We used PrimalScheme (https://primalscheme.com/) to generate an hMPXV primer scheme using a pre-outbreak A.1 lineage reference genome (GenBank accession: MT903345). The primer scheme comprises a total of 163 primer pairs with an amplicon length ranging between 1597 and 2497 bp (average length of 1977 bp). The primer scheme is compatible with current ARTIC and COVIDSeq SARS-CoV-2 sequencing protocols, and while validated only with Illumina library prep methods and sequencing platforms, it would likely see a high degree of success with other sequencing platforms such as the Oxford Nanopore Technologies MinION. Initial Validation: We validated our hMPXV primer scheme with clinical specimens at the Massachusetts Department of Public Health, Massachusetts State Public Health Laboratory under the IRB Project Titled “Rash Illness: Alternate Specimen Types and Sequencing” (protocol number 1917413). A total of 25 clinical specimens were included in this initial validation comprised of both throat and swabs of fluid from lesions of 8 individuals, belonging to the current outbreak-associated hMPXV B.1 lineage as determined by prior characterization at the Centers of Disease Control and Prevention. Ct values were determined with the non-variola orthopox diagnostic qPCR assay developed for use by the Laboratory Response Network (Rapid Diagnostic Testing for Response to the Monkeypox Outbreak — Laboratory Response Network, United States, May 17–June 30, 2022 | MMWR (cdc.gov)). Clinical samples ranged in cycle threshold (Ct) values from 15.03 (high viral concentration) to 34.63 (low viral concentration), and each sample was sequenced in parallel using a metagenomics approach and the provided amplicon-based approach. Extractions and sequencing analysis were performed in accordance with current biosafety guidance including extraction in a BSL-3 setting. An evaluation of site-specific biosafety practices should be developed in consultation with your organization’s biosafety officer. Libraries were prepared with the Illumina DNA prep kit and sequenced on the MiSeq (v2 kit running 2x150 nt reads). Consensus genomes were generated at 10X coverage using the TheiaCoV_Illumina_PE Workflow Series on Terra.bio. An hMPXV “fork” was developed for us by Curtis Kapsak from Theiagen, which included the hMPXV reference sequence, primer scheme, and consensus genome length, and can currently be accessed at: https://github.com/theiagen/public_health_viral_genomics/tree/cjk-MPXV-theiacov. We found comparable genome coverage between amplicon and metagenomic sequencing with low Ct (18; Figure 1A.) The library clean up stage of the amplicon based Illumina DNA prep protocol was conducted using the ‘standard DNA input’ option for comparison to metagenomics. Following optimization with 15 additional paired samples unrelated to the initial 10 samples, we found improved genome coverage with higher Ct samples (>25) using the ‘small PCR amplicon input’ option of the Illumina DNA prep protocol (Figure 1B.) Our findings highlight how amplicon-based approaches can significantly expand hMPXV sequencing to a wider variety of samples. Amongst samples with a low Ct (97%, with minimal amplicon drop-outs (Figure 2). Amplicons 11, 75, and 118 showed consistent drop-out across the sequenced samples, while none of the primers had mismatches, except for a single nucleotide mismatch in the 11_RIGHT primer. We did obtain coverage for these amplicons when sequencing clade IIa DNA from cultured virus (strain USA-2003; NR-4928) obtained from BEI Resources (NIAID, NIH). This suggests that the dropouts of these primers may be a specific issue related to the current hMPXV B.1 lineage genomes. As this protocol is still in development, we will further investigate performance as we continue to sequence additional samples. Conclusion: We developed an amplicon-based sequencing (PrimalSeq) approach for hMPXV that improved the depth and breadth of genome coverage with low viral concentration specimens as compared to metagenomic sequencing. This protocol...
- 12 December 2022
- Published by Springer Nature
Open AccessMonkeypox virus multiplexed PCR amplicon sequencing (PrimalSeq) v2
Version 5 Updates: Release of updated primer scheme (v1.1) that includes 11 additional primers to be spiked into the original primer scheme to improve coverage when sequencing clade I viruses. See materials tab for primer information and step 8 for new clade I reference and BED files. Complete validation study: https://doi.org/10.1101/2022.10.14.22280783 Background: The current global outbreak of human Monkeypox virus (hMPXV) concurrent with an ongoing SARS-CoV-2 pandemic has further highlighted the need for genomic surveillance and pathogen whole genome sequencing. While metagenomic and hybrid capture sequencing approaches were used to sequence many of the early mpox cases, the viability of these methods is dependent on samples with high viral DNA concentrations. Given the atypical clinical presentation of cases associated with the current outbreak and uncertainty regarding viral load across both the course of infection and anatomical body sites, there is a strong need for a more sensitive and broadly applicable sequencing approach. Amplicon-based sequencing (PrimalSeq) was initially developed for sequencing of Zika virus, and later adapted as the main sequencing approach for SARS-CoV-2. Here, we used PrimalScheme to design a primer scheme for hMPXV and we validated it with widely used SARS-CoV-2 sequencing protocols. Based on initial validation, our approach shows notably higher depth and breadth of coverage across the genome, particularly with higher PCR cycle threshold (Ct) samples, as compared to metagenomic sequencing. While further testing is needed, the early success of this approach has significant implications for sequencing efforts of the current hMPXV outbreak and serves as a proof of concept of amplicon-based sequencing for use with other large-genome DNA viruses and potentially bacterial genomes. Overview of Design: We used PrimalScheme (https://primalscheme.com/) to generate an hMPXV primer scheme using a pre-outbreak A.1 lineage reference genome (GenBank accession: MT903345). The primer scheme comprises a total of 163 primer pairs with an amplicon length ranging between 1597 and 2497 bp (average length of 1977 bp). The primer scheme is compatible with current ARTIC and COVIDSeq SARS-CoV-2 sequencing protocols, and while validated only with Illumina library prep methods and sequencing platforms, it would likely see a high degree of success with other sequencing platforms such as the Oxford Nanopore Technologies MinION. Initial Validation: We validated our hMPXV primer scheme with clinical specimens at the Massachusetts Department of Public Health, Massachusetts State Public Health Laboratory under the IRB Project Titled “Rash Illness: Alternate Specimen Types and Sequencing” (protocol number 1917413). A total of 25 clinical specimens were included in this initial validation comprised of both throat and swabs of fluid from lesions of 8 individuals, belonging to the current outbreak-associated hMPXV B.1 lineage as determined by prior characterization at the Centers of Disease Control and Prevention. Ct values were determined with the non-variola orthopox diagnostic qPCR assay developed for use by the Laboratory Response Network (Rapid Diagnostic Testing for Response to the Monkeypox Outbreak — Laboratory Response Network, United States, May 17–June 30, 2022 | MMWR (cdc.gov)). Clinical samples ranged in cycle threshold (Ct) values from 15.03 (high viral concentration) to 34.63 (low viral concentration), and each sample was sequenced in parallel using a metagenomics approach and the provided amplicon-based approach. Extractions and sequencing analysis were performed in accordance with current biosafety guidance including extraction in a BSL-3 setting. An evaluation of site-specific biosafety practices should be developed in consultation with your organization’s biosafety officer. Libraries were prepared with the Illumina DNA prep kit and sequenced on the MiSeq (v2 kit running 2x150 nt reads). Consensus genomes were generated at 10X coverage using the TheiaCoV_Illumina_PE Workflow Series on Terra.bio. An hMPXV “fork” was developed for us by Curtis Kapsak from Theiagen, which included the hMPXV reference sequence, primer scheme, and consensus genome length, and can currently be accessed at: https://github.com/theiagen/public_health_viral_genomics/tree/cjk-MPXV-theiacov. We found comparable genome coverage between amplicon and metagenomic sequencing with low Ct (18; Figure 1A.) The library clean up stage of the amplicon based Illumina DNA prep protocol was conducted using the ‘standard DNA input’ option for comparison to metagenomics. Following optimization with 15 additional paired samples unrelated to the initial 10 samples, we found improved genome coverage with higher Ct samples (>25) using the ‘small PCR amplicon input’ option of the Illumina DNA prep protocol (Figure 1B.) Our findings highlight how amplicon-based approaches can significantly expand hMPXV sequencing to a wider variety of samples. Amongst samples with a low Ct (97%, with minimal amplicon drop-outs (Figure 2). Amplicons 11, 75, and 118 showed consistent drop-out across the sequenced samples, while none of the primers had mismatches, except for a single nucleotide mismatch in the 11_RIGHT primer. We did obtain coverage for these amplicons when sequencing clade IIa DNA from cultured virus (strain USA-2003; NR-4928) obtained from BEI Resources (NIAID, NIH). This suggests that the dropouts of these primers may be a specific issue related to the current hMPXV B.1 lineage genomes. As this protocol is still in development, we will further investigate performance as we continue to sequence additional samples. Conclusion: We developed an amplicon-based sequencing (PrimalSeq) approach for hMPXV that improved the depth and breadth of genome coverage with low viral concentration specimens as compared to metagenomic sequencing. This protocol...